The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Irinotecan, cetuximab, and bevacizumab (CBI) versus irinotecan, cetuximab, and placebo (CI) in irinotecan-refractory metastatic colorectal cancer (mCRC): Results from an ACCRU network randomized phase II trial.
 
Marla Lipsyc-Sharf
No Relationships to Disclose
 
Fang-Shu Ou
No Relationships to Disclose
 
Matthew B. Yurgelun
No Relationships to Disclose
 
Douglas Adam Rubinson
Consulting or Advisory Role - Augmenix; Augmenix; Augmenix; Augmenix
 
Deborah Schrag
Stock and Other Ownership Interests - Merck (I); Merck (I); Merck (I); Merck (I)
Consulting or Advisory Role - JAMA-Journal of the American Medical Association; JAMA-Journal of the American Medical Association; JAMA-Journal of the American Medical Association; JAMA-Journal of the American Medical Association
Research Funding - AACR (Inst); AACR (Inst); AACR (Inst); AACR (Inst); GRAIL (Inst); GRAIL (Inst); GRAIL (Inst); GRAIL (Inst); Pfizer; Pfizer; Pfizer; Pfizer
Patents, Royalties, Other Intellectual Property - PRISSMM model is trademarked and curation tools are available to academic medical centers and government under creative commons license.; PRISSMM model is trademarked and curation tools are available to academic medical centers and government under creative commons license.; PRISSMM model is trademarked and curation tools are available to academic medical centers and government under creative commons license.; PRISSMM model is trademarked and curation tools are available to academic medical centers and government under creative commons license.
Travel, Accommodations, Expenses - IMEDEX; IMEDEX; IMEDEX; IMEDEX; Precision Medicine World Conference; Precision Medicine World Conference; Precision Medicine World Conference; Precision Medicine World Conference
Other Relationship - JAMA-Journal of the American Medical Association; JAMA-Journal of the American Medical Association; JAMA-Journal of the American Medical Association; JAMA-Journal of the American Medical Association
 
Shaker R. Dakhil
No Relationships to Disclose
 
Philip J. Stella
No Relationships to Disclose
 
Douglas Jay Weckstein
No Relationships to Disclose
 
Donald B. Wender
No Relationships to Disclose
 
Meredith Gail Faggen
No Relationships to Disclose
 
Tyler Zemla
No Relationships to Disclose
 
Erica N. Heying
No Relationships to Disclose
 
Samantha R Schuetz
No Relationships to Disclose
 
Stephanie Noble
No Relationships to Disclose
 
Jeffrey A. Meyerhardt
Honoraria - Cota Healthcare; Cota Healthcare; Cota Healthcare; Cota Healthcare; Ignyta; Ignyta; Ignyta; Ignyta; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma
Research Funding - Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Amgen; Amgen; Amgen; Amgen; Amgen (Inst); Amgen (Inst); AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Immuneering; Immuneering; Immuneering; Immuneering; Imugene; Imugene; Imugene; Imugene; Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly; Lilly; Lilly; Lilly; Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); NCCN; NCCN; NCCN; NCCN; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Regeneron; Regeneron; Regeneron; Regeneron; Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - NCCN; NCCN; NCCN; NCCN; NCI; NCI; NCI; NCI; Oncolytics; Oncolytics; Oncolytics; Oncolytics
Other Relationship - ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Exelixis; Exelixis; Exelixis; Exelixis; Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Polaris; Polaris; Polaris; Polaris; Sillajen; Sillajen; Sillajen; Sillajen
 
Charles S. Fuchs
Leadership - CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics
Stock and Other Ownership Interests - CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Entrinsic Health; Entrinsic Health; Entrinsic Health; Entrinsic Health
Consulting or Advisory Role - Agios; Agios; Agios; Agios; Bain Capital; Bain Capital; Bain Capital; Bain Capital; Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Dicerna; Dicerna; Dicerna; Dicerna; Entrinsic Health; Entrinsic Health; Entrinsic Health; Entrinsic Health; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; KEW; KEW; KEW; KEW; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Merrimack; Merrimack; Merrimack; Merrimack; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Unum Therapeutics; Unum Therapeutics; Unum Therapeutics; Unum Therapeutics
 
Kimmie Ng
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Lilly; Lilly; Lilly; Lilly; Seagen; Seagen; Seagen; Seagen; Tarrex Biopharma; Tarrex Biopharma; Tarrex Biopharma; Tarrex Biopharma
Research Funding - Celgene; Celgene; Celgene; Celgene; Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Pharmavite (Inst); Pharmavite (Inst); Pharmavite (Inst); Pharmavite (Inst); Trovagene; Trovagene; Trovagene; Trovagene